Prague Med. Rep. 2016, 117, 34-41
https://doi.org/10.14712/23362936.2016.3
Combination of Steroids and Azathioprine in the Treatment of Ormond’s Disease – A Single Centre Retrospective Analysis
References
1. 2012) Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann. Rheum. Dis. 71, 311–312.
< , M., Uhl, M., Wiech, T., Kollert, F., Thiel, J., Sass, J. O., Walker, U. A., Peter, H. H., Warnatz, K. (https://doi.org/10.1136/annrheumdis-2011-200148>
2. 2014) Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis. Urol. Int. 93, 320–325.
< , A. S., Kamper, L., Kukuk, S., Haage, P., Roth, S. (https://doi.org/10.1159/000357814>
3. 2014) The clinical spectrum of IgG4 related disease. Autoimmun. Rev. 13, 1203–1210.
< , P., Ramos-Casals, M., Bosch, X., Stone, J. H. (https://doi.org/10.1016/j.autrev.2014.08.013>
4. 2011) Abdominal infectious aortitis caused by Streptococcus pneumoniae: a case report and literature review. Ann. Vasc. Surg. 25, e9–e16.
< , C., Astudillo, L., Deelchand, A., Moskovitch, G., Sailler, L., Bossavy, J. P., Arlet, P. (https://doi.org/10.1016/j.avsg.2010.07.014>
5. 2011) Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann. Intern. Med. 155, 425–433.
< , L., Salvo, F., Tiraboschi, M., Bozzolo, E. P., Franchini, S., Doglioni, C. A., Manfredi, A., Baldissera, E., Sabbadini, M. G. (https://doi.org/10.7326/0003-4819-155-7-201110040-00005>
6. 2010) Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment, a pharmacogenomic test whose time has come. J. Clin. Pathol. 63, 288–295.
< , L. T., Berg, J. D. (https://doi.org/10.1136/jcp.2009.069252>
7. 2015) Clinicopathologic characteristics of IgG4-related retroperitoneal fibrosis among patients initially diagnosed as having idiopathic retroperitoneal fibrosis. Mod. Rheumatol. 25, 194–198.
< , Y. W., Hong, S., Kim, Y. J., Kim, Y. G., Lee, C. K., Yoo, B. (https://doi.org/10.3109/14397595.2014.931908>
8. 2013) Idiopathic vs. secondary retroperitoneal fibrosis: A clinicopathological study of 12 cases, with emphasis to possible relationship to IgG4-related disease. Virchows Arch. 463, 721–730.
< , J., Podhola, M., Kamaradova, K., Novak, I., Dobes, D., Brodak, M., Hacova, M., Ryska, A. (https://doi.org/10.1007/s00428-013-1480-7>
9. 2012) Rituximab therapy for chronic periaortitis. Ann. Rheum. Dis. 71, 1262–1264.
< , F., Corradi, D., Versari, A., Casali, M., Urban, M. L., Buzio, C., Vaglio, A. (https://doi.org/10.1136/annrheumdis-2011-201166>
10. 2001) Treatment of idiopathic retroperitoneal fibrosis using cyclosporine. Ann. Rheum. Dis. 60, 427–428.
< , A., Trapani, A., Leone, N., Actis, G. C., Rizzetto, M. (https://doi.org/10.1136/ard.60.4.427>
<PubMed>
11. 2012) Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol. Dial. Transplant. 27, 2819–2825.
< , L. G., Aarnoudse, A. J., Hendriksz, T. R., van Bommel, E. F. (https://doi.org/10.1093/ndt/gfr779>
12. 2011) Aortitis: Imaging spectrum of the infectious and inflammatory conditions of the aorta. Radiographics 31, 435–441.
< , C. S., Ocazionez, D., Suri, R., Vargas, D. (https://doi.org/10.1148/rg.312105069>
13. 2011) Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann. Intern. Med. 154, 31–36.
< , P. J., Feeley, N. Jr., Sozio, S. M. (https://doi.org/10.7326/0003-4819-154-1-201101040-00005>
14. 2013) Imaging vasculitis. Best Pract. Res. Clin. Rheumatol. 27, 107–118.
< , W. A. (https://doi.org/10.1016/j.berh.2013.01.001>
15. 2010) The birthday of a new syndrome: IgG4-related diseases constitute a clinical entity. Autoimmun. Rev. 9, 591–594.
< , H., Yamamoto, M., Suzuki, C., Naishiro, Y., Shinomura, Y., Imai, K. (https://doi.org/10.1016/j.autrev.2010.05.003>
16. 2006) Retroperitoneal fibrosis. Lancet 367, 241–251.
< , A., Salvarani, C., Buzio, C. (https://doi.org/10.1016/S0140-6736(06)68035-5>
17. 2013) Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum. 65, 2469–2475.
< , A., Catanoso, M. G., Spaggiari, L., Magnani, L., Pipitone, N., Macchioni, P., Pulsatelli, L., Nicastro, M., Becchi, G., Corradi, D., Versari, A., Boiardi, L., Salvarani, C. (https://doi.org/10.1002/art.38032>
18. 2009) Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore) 88, 193–201.
< , E. F., Jansen, I., Hendriksz, T. R., Aarnoudse, A. L. (https://doi.org/10.1097/MD.0b013e3181afc420>
19. 2009) Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am. J. Surg. Pathol. 33, 1812–1819.
, Y., Onodera, M., Inoue, D., Kitao, A., Matsui, O., Nohara, T., Namiki, M., Kasashima, S., Kawashima, A., Matsumoto, Y., Katayanagi, K., Murata, T., Ishizawa, S., Hosaka, N., Kuriki, K., Nakanuma, Y. (
20. 2012) Retroperitoneal and aortic manifestations of immunoglobulin G4-related disease. Semin. Diagn. Pathol. 29, 212–218.
< , Y., Kasashima, S., Inoue, D. (https://doi.org/10.1053/j.semdp.2012.07.003>